ClinicalTrials.gg
Not yet recruitingNCT07863609Updated Oct 15, 2026

Phase 1b Study of TX002100 in Participants With Hematologic Support-Dependent Hereditary Hemorrhagic Telangiectasia (HHT)

A Phase 1 interventional study of TX002100 in Hereditary Hemorrhagic Telangiectasia (HHT), sponsored by Tectonic Operating Company, Inc.. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Tectonic Operating Company, Inc. · Phase 1, Interventional, and Treatment

How we know

Updated Oct 15, 2026Start date movedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The primary purpose of this study is to assess the safety and tolerability of TX002100 in participants with hereditary hemorrhagic telangiectasia (HHT). The study will also look at whether TX002100 reduces the need for blood or iron treatments, and whether it improves blood counts, such as hemoglobin levels.

02

Conditions studied

  • Hereditary Hemorrhagic Telangiectasia (HHT)
03

In context

Telangiectasia, Hereditary Hemorrhagic

106 studies on the registry are indexed under Telangiectasia, Hereditary Hemorrhagic; 24 are open to participants now.

This study's planned enrollment of 20 is below the median of 33 across 61 interventional studies indexed under Telangiectasia, Hereditary Hemorrhagic.

Browse Telangiectasia, Hereditary Hemorrhagic studies →

Lead sponsor

Tectonic Operating Company, Inc. is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults with HHT who need regular intravenous iron or blood transfusions.
  2. Females of and male participants must agree to comply with the requirements.
  3. Able to understand and is willing and able to comply with the study requirements and study procedures and agrees to participate in the study by giving written .

Exclusion criteria

Exclusion Criteria:

  1. History of anemia of any cause other than HHT-related bleeding, or any other inherited bleeding disorder aside from HHT.
  2. Has undergone or is anticipated to undergo liver transplantation.
  3. Medical conditions or comorbidities that, in the opinion of the investigator, would interfere with study compliance or data interpretation; or, in the opinion of the Investigator, taking part in the study would jeopardize the safety of the patient.
  4. History of hemorrhage from untreated pulmonary arteriovenous malformations (AVMs) manifesting as hemoptysis or hemothorax within 12 weeks before screening.
  5. Receipt of any vaccination within 2 weeks prior to first dose.
  6. Recent major surgery (within 4 weeks before the screening visit) or planned major surgery during the study.
  7. GI bleeding due to non-HHT disease (e.g., GI ulcers, diverticulosis), in the opinion of the investigator, within 6 months before screening.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    TX002100

    Participants will receive subcutaneous (SC) injection of TX002100 administered weekly.

    Biological: TX002100

Interventions

  • BiologicalTX002100

    Subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events (AEs), including serious adverse events (SAEs)

    Time frame: Screening up to Day 225

  2. Incidence of clinically significant changes from baseline in safety laboratory assessments and other safety assessments

    Time frame: Baseline up to Day 225

Secondary outcomes

  1. To assess hematologic support score change from baseline calculated over the 12 weeks preceding the time point

    Time frame: Baseline up to 6 months

  2. To assess hematologic impact score

    Time frame: Measured at 6 months

  3. To assess hemoglobin change from baseline

    Time frame: Baseline up to 6 months

  4. Change from baseline in the following calculated over the 12 weeks preceding the time point: - Total parenteral iron (mg) infused - Number of pRBCs transfused

    Time frame: Baselineup to 6 months

07

Study locations

No study locations are listed for this record.

08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Dec 2026; primary completion for Apr 2028, 15 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: start Jan 2027 → Dec 2026, primary completion Dec 2028 → Apr 2028 and completion Dec 2028 → Jul 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2026
First posted
Oct 7, 2026
StartEst.
Dec 31, 2026was Jan 2027
Primary completionEst.
Apr 30, 2028was Dec 2028
CompletionEst.
Jul 30, 2028was Dec 2028
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jan 31, 2027→Dec 31, 2026
Oct 15, 2026
Primary completion
Dec 31, 2028→Apr 30, 2028
Oct 15, 2026
Study completion
Dec 31, 2028→Jul 30, 2028
Oct 15, 2026
Registered
First appeared on the registry
Oct 7, 2026
Show all 2 updates
  1. Oct 15, 2026
    Start date Jan 31, 2027→Dec 31, 2026
    Primary completion Dec 31, 2028→Apr 30, 2028
    Study completion Dec 31, 2028→Jul 30, 2028
  2. Oct 7, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07863609
Lead sponsor
Tectonic Operating Company, Inc.
Responsible party
Sponsor
First posted
Oct 7, 2026
Start date
Dec 31, 2026 (estimated)
Primary completion
Apr 30, 2028 (estimated)
Completion
Jul 30, 2028 (estimated)
Last update
Oct 15, 2026

Study contacts

Clinical Trials
Contact
ClinicalTrials@tectonictx.com
+1 339 337 4053

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion